Dihydropyrimidine Dehydrogenase
DPYD breaks down fluoropyrimidine chemotherapy drugs (5-FU, capecitabine). A small percentage of people carry reduced-function variants that cause the drug to accumulate to toxic levels. This is one of the few pharmacogenetic tests that is mandatory in many oncology guidelines before starting treatment.
Gene2Rx covers 2 medications with published pharmacogenetic guidance for DPYD, drawn from CPIC and FDA sources. Each drug links to its full pharmacogenetics page.
These branded medications include at least one active ingredient whose metabolism or action involves DPYD. Each links to its full pharmacogenetic breakdown.
This page lists drugs affected by DPYD. A Gene2Rx report tells you which metabolizer group you fall into, and what that means for every medication on this list.
Get your report Look up a medicationInformational only, not medical advice. The presence of a DPYD pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.